Nanoparticle-Mediated Cancer Radiation Therapy

Nanoparticle-mediated radiation therapy harnesses tailored nanoscale constructs to improve tumour control by amplifying the effects of ionising radiation. By incorporating high-atomic-number elements such as gold, hafnium or gadolinium, these particles intensify local energy deposition and promote the generation of reactive oxygen species, thereby increasing DNA damage in cancer cells. Surface modification with targeting ligands and responsive coatings facilitates selective accumulation in tumours and minimises off-target toxicity. Furthermore, integration of functional payloads—including oxygen carriers, chemotherapeutic prodrugs or immunostimulatory molecules—enables synergistic combinatorial treatments under image guidance. Such platforms not only overcome hypoxia-induced radioresistance but also elicit systemic antitumour immunity, enhancing abscopal responses when paired with checkpoint blockade. The global significance of this approach lies in its potential to improve treatment outcomes across diverse cancer types while reducing normal tissue complications. Continued advances in materials design, biocompatibility and clinical translation are poised to establish nanoparticle-mediated radiotherapy as a cornerstone of precision oncology.

Research from Nature Portfolio

Recent studies have introduced a self-assembling gadolinium nanotexaphyrin vesicle loaded with myoglobin to alleviate tumour hypoxia and achieve markedly enhanced radiosensitisation, alongside real-time dual-modality imaging for guided delivery. A radio-immunostimulant nanomedicine targeting myeloid cells has been shown to catalyse endogenous hydrogen peroxide into oxygen, thereby relieving hypoxia and potentiating radiotherapy to enhance susceptibility to checkpoint inhibition in post-surgical models. In addition, a polylysine–iron oxide–CpG nanoparticle used in conjunction with radiation amplifies tumour antigen presentation, shifts tumour-associated macrophage profiles and upregulates type I interferon signalling, resulting in robust in situ vaccine effects and improved responses to immune checkpoint blockade.

Nanoparticle-Mediated Cancer Radiation Therapy publication trend

The graph below shows the total number of articles in nanoparticle-mediated cancer radiation therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Radiosensitiser: An agent that increases tumour cell sensitivity to ionising radiation by enhancing energy deposition or reactive species generation.

Reactive oxygen species (ROS): Chemically reactive molecules derived from oxygen that induce DNA damage and cell death under radiation.

Tumour hypoxia: A low-oxygen microenvironment in solid tumours that reduces radiotherapy efficacy and promotes resistance.

Abscopal effect: A systemic antitumour response in non-irradiated lesions following local radiation.

Theranostic: A multifunctional agent combining therapeutic and diagnostic capabilities for treatment monitoring.

Metal–organic framework (MOF): A porous nanostructure composed of metal ions and organic ligands used for drug delivery and radiosensitisation.

References

1. Myoglobin-loaded gadolinium nanotexaphyrins for oxygen synergy and imaging-guided radiosensitization therapy. Nature Communications (2023).
2. Nanoscale Metal–Organic Framework with an X‑ray Triggerable Prodrug for Synergistic Radiotherapy and Chemotherapy. Journal of the American Chemical Society (2023).
3. Oxygen‐Enriched Metal‐Phenolic X‐Ray Nanoprocessor for Cancer Radio‐Radiodynamic Therapy in Combination with Checkpoint Blockade Immunotherapy. Advanced Science (2020).
4. Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy. Theranostics (2020).
5. Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade. Nature Communications (2022).